Aclaris Therapeutics' high P/S ratio, alongside declining revenue and the industry's predicted 49% annual growth, could be a significant risk for shareholders and potential investors.
$Aclaris Therapeutics(ACRS.US)$Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis 4 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE
Aclaris Therapeutics股票討論區
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
暫無評論